切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2016, Vol. 05 ›› Issue (01) : 11 -15. doi: 10.3877/cma.j.issn.2095-3224.2016.01.03

所属专题: 文献

专家论坛

胃癌放射治疗进展
朱远1,()   
  1. 1. 310022 杭州,浙江省肿瘤医院放疗科,浙江省放射治疗学重点实验室
  • 收稿日期:2016-02-14 出版日期:2016-02-25
  • 通信作者: 朱远
  • 基金资助:
    浙江省自然科学基金(LY14H60009)

Advances of radiotherapy for gastric cancer

Yuan Zhu1,()   

  1. 1. Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Radiation Oncology, Hangzhou 310022, China
  • Received:2016-02-14 Published:2016-02-25
  • Corresponding author: Yuan Zhu
  • About author:
    Corresponding author: Zhu Yuan, Email:
引用本文:

朱远. 胃癌放射治疗进展[J/OL]. 中华结直肠疾病电子杂志, 2016, 05(01): 11-15.

Yuan Zhu. Advances of radiotherapy for gastric cancer[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(01): 11-15.

胃癌是国内外常见的恶性肿瘤之一,手术是胃癌的主要治疗手段,但局部晚期胃癌单纯手术很难达到根治。化疗在局部晚期胃癌新辅助及辅助治疗中的地位已比较肯定,但放疗或放化疗的地位仍有争议。

Gastric cancer is one of the most common malignancy in the world, surgery is the main treatment management of gastric cancer, but surgery alone is difficult for the radical treatment in locally advanced gastric cancer. The role of neoadjuvante and adjuvante chemotherapy in advanced gastric cancer is sure, but the role of radiotherapy or chemoradiocherapy is yet controversial.

[1]
陈万青,张思维,曾红梅,等.中国肿瘤登记地区2010年恶性肿瘤发病和死亡分析.中国肿瘤,2014,23(1): 1-10.
[2]
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2015. CA Cancer J Clin, 2015, 65(1): 5-29.
[3]
Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA, 2010, 303(17): 1729-1737.
[4]
Zhang ZX, Gu XZ, Yin WB, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)-report on 370 patients. Int J Radiat Oncol Biol Phys, 1998, 42(5): 929-934.
[5]
Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol, 2004, 22(14): 2774-2780.
[6]
Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol, 2005, 23(6): 1237-1244.
[7]
Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol, 2006, 24(24): 3953-3958.
[8]
Trip AK, Poppema BJ, van Berge Henegouwen MI, et al. Preoperative chemoradiotherapy in locally advanced gastric cancer, a phase I/II feasibility and efficacy study. Radiother Oncol, 2014, 112(2): 284-288.
[9]
Fields RC, Strong VE, Gonen M, et al. Recurrence and survival after pathologiccomplete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. Br J Cancer, 2011, 104(12): 1840-1847.
[10]
Diaz-Gonzalez JA, Rodriguez J, Hernandez-Lizoain JL, et al. Patterns of response after preoperative treatment in gastric cancer. Int J Radiat Oncol Biol Phys, 2011, 80(3): 698-704.
[11]
Pepek JM, Chino JP, Willett CG, et al. Preoperative chemoradiotherapy for locally advanced gastric cancer. Radiation Oncology, 2013, 8(1): 6-13.
[12]
Kumagai K, Rouvelas I, Tsai JA, et al. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: A direct and adjusted indirect comparison meta-analysis. Eur J Surg Oncol, 2015, 41(3): 282-294.
[13]
Leong T, Smithers M, Michael M, et al. TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG). J Clin Oncol, 2012, 30 (15 Suppl): TPS4141.
[14]
Martinez-Monge R, Calvo A F, Azinovic I. Patterns of Failure and Long-Term Results in High-Risk Resected Gastric Cancer Treated With Postoperative Radiotherapy With or Without Intraoperative Electron Boost. J Surg Oncol, 1997, 66(1): 24-29.
[15]
Glehen O, Peyrat P, Beaujard AC, et al. Pattern of failures in gastric cancer patients with lymph node involvement treated by surgery, intraoperative and external beam radiotherapy. Radiother Oncol, 2003, 67(2): 171-175.
[16]
Calvo F, Sole C, Obregon R, et al. Intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma: topography of locoregional recurrences and long-term outcomes. Clin Transl Oncol, 2013, 15(6): 443-449.
[17]
Fu S, Lu JJ, Zhang Q, et al. Intraoperative radiotherapy combined with adjuvant chemoradiotherapy for locally advanced gastric adenocarcinoma. Int J Radiat Oncol Biol Phys, 2008, 72(5): 1488-1494.
[18]
Debenham B, Hu K, Harrison L. Present status and future directions of intraoperative radiotherapy. Lancet Oncol, 2013, 14(11): e457-464.
[19]
Zhang Q, Tey J, Peng L, et al. Adjuvant chemoradiotherapy with or without intraoperative radiotherapy for the treatment of resectable locallyadvanced gastric adenocarcinoma. Radiother Oncol, 2012, 102(1): 51-55.
[20]
Drognitz O, Henne K, Weissenberger C, et al. Long-term results after intraoperative radiation therapy for gastric cancer. Int J Radiat Oncol Biol Phys, 2008, 70(3): 715-721.
[21]
D′Angelica M, Gonen M, Brennan MF, et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg, 2004, 240(5): 808-816.
[22]
Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol, 2012, 30(19): 2327-2333.
[23]
Fuchs CS, Tepper JE, Niedzwiecki D, et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol, 2011, 29(15_suppl; abstr 4003): 256s.
[24]
Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial. J Clin Oncol, 2012, 30(3): 268-273.
[25]
Park SH, Sohn TS, Lee J, et al. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. J Clin Oncol, 2015, 33(28): 3130-3136.
[26]
Zhu WG, Xua DF, Pu J, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol, 2012, 104(3): 361-366.
[27]
Dikken JL, van Sandick JW, Maurits Swellengrebel HA, et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS) . BMC Cancer, 2011, 11: 329.
[28]
Qin H L, Lin CH, Zhang XL. Evaluation of intraoperative radiotherapy for gastric carcinoma with D2 and D3 surgical resection. World J Gastroenterol, 2006, 12(43): 7033-7037.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[2] 曹琮沅, 黄烁金, 何倩婷, 王安训. 平阳霉素复合剂治疗口腔颌面部脉管畸形的有效性和安全性[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(06): 368-374.
[3] 李国新, 陈新华. 全腹腔镜下全胃切除术食管空肠吻合的临床研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 1-4.
[4] 陈方鹏, 杨大伟, 金从稳. 腹腔镜近端胃癌切除术联合改良食管胃吻合术重建His角对术后反流性食管炎的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 15-18.
[5] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[6] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[7] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[8] 任佳, 马胜辉, 王馨, 石秀霞, 蔡淑云. 腹腔镜全胃切除、间置空肠代胃术的临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 31-34.
[9] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[10] 王露, 周丽君. 全腹腔镜下远端胃大部切除不同吻合方式对胃癌患者胃功能恢复、并发症发生率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 92-95.
[11] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[12] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[13] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[14] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[15] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?